SG-55
SG-55 is a selective, noncompetitive and orally active AKR1C3 inhibitor with an IC50 of 5 nM and a Ki of 10 nM. SG-55 shows >2000-fold selectivity for AKR1C3 over AKR1C1, AKR1C2, and AKR1C4 (> 10 μM). SG-55 increases the ratio of reduced/oxidized nicotinamide adenine dinucleotide phosphate (NADPH/NADP+), decreases the ratio of reduced/oxidized glutathione (GSH/GSSG), and induces DNA double-strand breaks. SG-55 can overcome Osimertinib (HY-15772) resistance mediated by EGFR C797S triple mutation in non-small cell lung cancer (NSCLC).
For research use only. We do not sell to patients.
- Formula: C19H17N3O2
- Molecular Weight:319.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
AKR1C3 5 nM (IC50) |
AKR1C3 10 nM (IC50) |
SG-55 (0.5-100 μM; 72 h) does not inhibits the cell growth of AKR1C3-overexpressing PC-9/OR cell line (PC-9 EGFR 19Del/T790M/C797S cells)[1].
SG-55 (72 h) at 10 μM, 20 μM and 50 μM decreased the IC50 of Osimertinib (100-500 nM) in PC-9/OR cells from 2.59 μM to 1.30 μM, 0.43 μM and 0.23 μM, respectively, corresponding to resistance-reversal factors of 2, 6 and 11-fold[1].
SG-55 (10 μM) cooperates with Osimertinib to suppress clonogenicity (14 days), curtail migration (24 h), and amplify cycle arrest (24 h) and apoptosis (72 h), thereby conferring significant sensitization in PC-9/OR cells[1].
SG-55 (10 μM; 72 h)-mediated AKR1C3 inhibition elevates the NADPH/NADP+ ratio, disrupts the GSH cycle, breaks redox balance, and amplifies oxidative damage, thereby overcoming EGFR mutation-driven Osimertinib resistance in PC-9/OR cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:AKR1C3-overexpressing PC-9/OR cell lines
-
Concentration:10 μM plus Osimertinib (100 nM)
-
Incubation Time:72 h
-
Result:AKR1C3 Inhibition enhanced Osimertinib-induced apoptosis.
-
Cell Line:AKR1C3-overexpressing PC-9/OR cell lines
-
Concentration:10 μM plus Osimertinib (100 nM)
-
Incubation Time:24 h
-
Result:Osimertinib alone imposed a G0/G1 arrest, whereas the addition of the compound shifted the cycle distribution to G2/M accumulation.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c nude mice (6 weeks old) were inoculated subcutaneously in the right flank with 3 × 107 PC-9/OR cells (100 μL) to establish xenografts[1].
-
Dosage:10 mg/kg plus Osimertinib (5 mg/kg p.o.)
-
Administration:p.o.; every 1 days; for 21 days
-
Result:The tumor-growth inhibition (TGI) values of 15.6%.
When used in combination with osimertinib, the TGI was 93.1%.
No significant body-weight loss was observe.
Chemical Information
-
Molecular Weight 319.36
-
Formula C19H17N3O2
-
SMILES
N#CC1=CC2=C(C=C1)CN(C(C3=CC(C(C4CC4)=O)=CN3)=O)CC2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SG-55 Related Classifications
HY-181542 Related Classifications
Powered by Bioz